Modulation of the endocannabinoid system by the administration of exogenous agonists and selective antagonists has been shown to have potential to attenuate the contribution of inflammation to secondary injury in the CNS. The two most well-defined receptors are the CB1 and CB2 receptors. CB2, the cannabinoid receptor expressed primarily on hematopoietic cells and activated microglia, mediates the immunoregulatory functions of cannabinoids. The involvement of CB2 in central nervous inflammation has been demonstrated by using both endogenous and exogenous ligands. We showed previously that CB2 selective agonists inhibited leukocyte rolling and adhesion to CNS microvasculature and ameliorate clinical symptom in both chronic and remitting-relapsing EAE models; and our previous studies also demonstrated therapeutic potential of CB2 agonist improving recovery following spinal cord injury in the mouse. The goal of the current investigation was to evaluate the mechanisms through which administration of a selective cannabinoid-2 (CB2) agonist modifies inflammatory responses and helps to improve function following the injury in central nervous system. In the EAE project, we showed that Gp1a, a highly selective CB2 agonist with a four log higher affinity for CB2 than CB1, reduced clinical scores and facilitated recovery in EAE in conjunction with long term reduction in demyelination and axonal loss. We also established that Gp1a affected EAE through at least two different mechanisms, i.e. an early effect on Th1/Th17 differentiation in peripheral immune organs, and a later effect on the accumulation of pathogenic immune cells in the CNS, associated with reductions in the expression of CNS and T cell chemokine receptors, chemokines and adhesion molecules. This is the first report on the in vivo CB2-mediated Gp1a inhibition of Th17/Th1 differentiation. We also confirmed the Gp1a-induced inhibition of Th17/Th1 differentiation in vitro, both in non-polarizing and polarizing conditions. The CB2-induced inhibition of Th17 differentiation is highly relevant in view of recent studies emphasizing the importance of pathogenic self-reactive Th17 cells in EAE/MS. In spinal cord injury project, we showed that spinal cord injury mice CB2 agonist O-1966 (with affinities to the CB1 and CB2 receptors of 5055±984 and 23±2.1 nM, respectively) had improved motor function, autonomic function. They also had significant reductions in CXCL-9, CXCL-11, dramatic reductions in IL-23p19 expression and its receptor IL-23r, and reduction in the number of immunoreactive microglia. The results reported in this thesis, demonstrated that the combined effect on Th17 differentiation and immune cell accumulation into the CNS, may contribute to the usefulness of CB2 selective ligands as potential therapeutic agents in neuroinflammation. / Physiology

Across almost all types of neurological pathophysiology, inflammation and corresponding breakdown of the Blood Brain Barrier (BBB) are hallmarks of injury/disease progression. In fact, BBB disruption can occur early during neuropathophysiological development, in many cases even before neurological and cognitive impairments become apparent. Whether as an early causative factor, a side effect, or both as it pertains to neurological injury/disease, BBB breakdown and dysfunction represents a novel and under investigated target for therapeutic development, especially for neurological pathologies with unmet therapeutic needs. Toward this goal, the endocannabinoid system (ECS) has emerged as a promising biological target for drug discovery efforts. Particularly, the Cannabinoid 2 Receptor (CB2R) has been proposed as a druggable target due to its anti-inflammatory effects and since it is not associated with the neurological side effect profile representative of Cannabinoid 1 Receptor (CB1R) drugs. Interestingly, neuroinflammatory conditions promote upregulation of CB2R on brain microvascular endothelial cells (BMVECs) suggesting a possible role toward resolution of inflammation in this cell type. Moreover, previous research has shown promising effects of CB2R agonists on cerebrovascular function, although these effects cannot be directly attributed to endothelial CB2R. The central hypothesis of this research is that endothelial CB2R activation confers effects which are vascular protective and that promote BBB repair, (irrespective of the effects of CB2R in other central nervous system (CNS) cell types). To address this hypothesis, endothelial CB2R expression dynamics were assessed following experimental Traumatic Brain Injury (TBI) followed by a series of assays to assess the therapeutic potential of a novel chromenopyrazole based CB2R agonist, PM289. Results of these experiments demonstrated upregulation of CNR2, the gene which encodes CB2R, following in vivo experimental TBI and in vitro cytokine induced inflammation. Moreover, PM289 exhibited robust CB2R-dependent therapeutic potential by partially restoring TNFa-induced physical barrier disruption, attenuating TNFa-induced ICAM1 upregulation, and promoting rapid monolayer repair following electrolytic wound. Mechanistically, these effects may be explained via CB2R-dependent inhibition of NFkB/P65 signaling. Overall, these results are supportive of the notion that CB2R in BMVECs could aid in vascular protection and promote BBB function in the context of neuroinflammation. Future studies are warranted to understand the in vivo therapeutic efficacy of PM289 in a variety of injury/disease models. Additionally, alternative cell signaling mechanisms should be considered including a comprehensive examination of potential interplay between ECS components and candidates that fall under the umbrella of the endocannabionoidome (ECBome). / Biomedical Sciences

CP47,497 and other synthetic cannabinoid compounds were incipiently synthesized as research tools to investigate the mechanisms by which marijuana affects the brain and to aid in the development of therapeutic agents. Recently, these cannabinoid compounds have resurfaced in the designer drug market, marketed as “herbal incense products” (HIPs). Their popular use has resulted in an alarming rate of reported adverse effects and toxicities. Current legislation classified CP47,497 and several other synthetic cannabinoids compounds as Schedule I agents, but abuse of these compounds persists with serious consequences to public health and safety. In vivo studies examining the behavioral consequences of abused synthetic cannabinoids are limited. As a result, the goals of this research were to elucidate the acute and chronic pharmacological effects of CP47,497 and to develop a bioanalytical method for CP47,497 drug detection in mice. Cannabimimetic effects were evaluated in well-established in vivo models, the tetrad paradigm and drug discrimination assay. The tetrad test is comprised of four outcome measures sensitive to the primary psychoactive cannabinoid present in marijuana, delta-9-tetrahydrocannabinol (THC): catalepsy (bar test), antinociception (tail withdrawal latency), hypothermia, and decreases in spontaneous locomotor activity. While many pharmacological agents can produce one or a subset of these tetrad effects, drugs that activate CB1 receptors produce characteristic effects in all four parameters. An HPLC/MS/MS method was developed and confirmed the presence of CP47,497 in brain. We investigated whether CB1 receptors mediate the pharmacological effects of CP47,497. Cumulative dose-response experiments determined CP47,497 is more potent than THC in vivo in using multiple behavioral assays. Complementary pharmacological (CB1 receptor antagonist, rimonabant) and genetic (CB1 (-/-) mice) approaches were used to investigate whether CB1 receptors mediate the effects of CP47,497. Rimonabant (3 mg/kg or 10 mg/kg, depending on independent measure) blocked all cannabinoid-like pharmacological effects of CP47,497. Supporting these findings, CB1(-/-) mice were resistant to cannabimimetic effects of CP47,497. CP47,497 fully substituted for THC in the drug discrimination assay, with a potency of more than 5 times that of THC. Collectively, these results indicate that CP47,497 is markedly more potent (i.e. 5-8 fold) than THC, and its repeated administration produces tolerance to the cataleptic, antinociceptive, hypothermic and hypolocomotor effects in mice, with significant presentation of somatic withdrawal signs (paw flutter and head shakes) upon drug cessation. These findings are consistent with the high incidence of adverse events in humans abusing synthetic cannabinoids.

Genetic deletion or pharmacological blockade of the CB1 receptor has been reported to impair extinction learning in aversive conditioning (i.e., conditioned fear and Morris water maze) paradigms, but not in operant procedures in which food reinforcement is earned. It is difficult to discern whether the differential effects caused by CB1 receptor disruption on extinction result from the hedonics (i.e., aversive vs. appetitive) or is related to the required responses associated with these disparate tasks. In order to evaluate whether the hedonics is the determining factor, we used either aversive (i.e., escape from bright lights and air turbulence) or appetitive (i.e., to gain access to water) motivators in the Barnes maze task, a model in which mice are required to enter a hidden goal box. Administration of the CB1 receptor antagonist, rimonabant, disrupted extinction learning under aversive conditions, but not under appetitive conditions. This is the first study to show a differential effect of rimonabant on extinction in a task that required identical motor behaviors, but only differed in hedonic nature of the reinforcer. In addition, genetic ablation of CB1 receptor signaling impaired acquisition of the task under both aversive and appetitive conditioning procedures. Conversely, enhancing endocannabinoid signaling, via genetic deletion of the FAAH enzyme, accelerated acquisition of the task under aversive, but not appetitive, conditioning procedures. Accordingly, these data strongly support the hypothesis that the endogenous cannabinoid system plays a necessary role in the extinction of aversively motivated behaviors, but is expendable in appetitively motivated behaviors. While these findings underscore concerns over potential side effects associated with CB1 receptor antagonists, they also suggest that stimulating the endogenous cannabinoid system may be a promising pharmacological approach to treat maladaptive behaviors that arise from stress or trauma.

1 Abstract BASIC POSTULATES: It is common the people affected by ADHD consume addictive substances such as alcohol, marihuana, heroin, sedatives, analgetics, nicotine, caffeine, sugar, cocaine or street-produced amphetamines, seeking relief from their sensations of motorical unease and to disturb their rationalising and thinking (Downs, 2013). Using these substances subjectively improves their abilities, reducing the undesired and unpleasant sensations emanating from the ADHD, possibly even creating enjoyable and desirable moods. The resulting problem is, this self-medication causes troubles in many aspects, detectable only gradually after longer periods of consumption. What starts as an effort to paliate the undesirable symptoms of ADHD and other effects thereof, progressively becomes seeking a solution to harmful consumption of marihuana and, in extreme cases, additiction to cannabinoids (Jensen, 2013). OBJECTIVES: The purpose of this thesis is to analyse adult ADHD, regardless of whether they have been diagnosed, yet with perduring symptoms, and who have never been medicated and now use marihuana as self-medication. The main objective is to determine whether respondents subjectively realise when cannabis helps them to relieve their internal unease and when not. Besides, it is also to learn if we can...

O sistema endocanabinóide (eCB) tem sido reconhecido como um importante modulador da homeostase energética e recentemente estudos o apontam como um possível integrador da homeostase hidroeletrolítica. Estudos recentes do nosso laboratório demonstraram a participação do receptor canabinóide do tipo 1 (CB1R) no controle da secreção neurohipofisária em resposta a expansão hipertônica do volume extracelular. Dessa forma, o presente trabalho visou esclarecer a participação do sistema eCB, particularmente do CB1R, nas respostas neuronais, neuroendócrinas e comportamentais induzidas pela sobrecarga salina de 4 dias (SS). Uma vez que os animais em SS apresentam hipofagia induzida pela hiperosmolalidade, buscou-se avaliar as vias de integração do controle da homeostase energética e do balanço hidroeletrolítico por meio da introdução de um grupo em dieta pareada (pair fed, PF). De forma a investigar a hipótese acima, utilizou-se como ferramenta farmacológica o agonista seletivo CB1R, araquidonil-2-cloroetilamida (ACEA - 0,1g/5L), administrado por via intracerebroventricular (icv). Inicialmente, nosso trabalho mostrou que a SS promoveu aumento da expressão de CB1R tanto nos núcleos supra-óptico (NSO) e paraventricular (NPV) do hipotálamo quanto em estruturas da lâmina terminal [órgão subfornicial (SFO), o órgão vasculoso da lâmina terminal (OVLT) e o núcleo pré-óptico mediano (MnPO)]. Tais observações foram reforçadas pela análise microscópica destas regiões cerebrais por imunofluorescência, que evidenciou aumento da imunomarcação para CB1R no NPV, NSO e SFO em animais submetidos a SS. Estes resultados também mostraram que a maioria dos terminais pré-sinápticos CB1R-positivos estão localizados predominantemente na porção ventral do NSO, na qual predominam neurônios vasopressinérgicos. Os dados mostram ainda que todas as respostas induzidas pela SS foram revertidas após a reintrodução dos líquidos (RL, água e NaCl 0,3M). Já no grupo PF, não foram observadas alterações na expressão de CB1R em nenhuma das áreas avaliadas. No entanto, após a RL, os animais PF apresentaram hipoosmolalidade plasmática e aumento da expressão de CB1R na LT, sendo este último efeito aparentemente mediado por um aumento da expressão deste receptor no SFO. Em animais normoidratados, a administração central de ACEA produziu um aumento significativo na ingestão alimentar, sendo esta resposta ausente nos animais submetidos a SS, apesar do aumento da expressão de CB1R no hipotálamo verificada neste grupo. Entretanto, o pré-tratamento com ACEA foi capaz de potencializar a ingestão de água induzida pela SS, não produzindo efeitos significativos sobre este parâmetro no grupo PF. Este estudo demonstrou ainda que a SS não alterou as concentrações plasmáticas de angiotensina II (ANGII), porém promoveu aumento signficativo nas concentrações plasmáticas de corticosterona, vasopressina (AVP) e ocitocina (OT), além de diminuir a secreção de peptídeo natriurético atrial (ANP). Em animais submetidos a SS, o prétratamento com ACEA potencializou a secreção de corticosterona e preveniu o aumento da secreção de AVP e OT. Por outro lado, não foram observados efeitos da administração de ACEA sobre a secreção de ANP e ANGII induzida pela SS. Após a RL, o grupo SS apresentou normalização das concentrações plasmáticas hormonais, não sendo observados quaisquer efeitos da administração de ACEA nestas condições experimentais. No grupo PF, por sua vez, após a RL foi observada diminuição na secreção de OT e aumento nas concentrações plasmáticas de ANGII, efeitos estes não alterados pelo pré-tratamento com ACEA. Em conjunto, nossos dados sugerem que o CB1R participa ativamente das respostas homeostáticas comportamentais e neuroendócrinas desencadeadas pela SS, sendo estas respostas especificamente relacionadas ao controle da homeostase hidrossalina e não secundárias à hipofagia induzida pela hiperosmolalidade. Desta forma, conclui-se que a participação do CB1R na homeostase hidroeletrolítica ocorre em paralelo e independentemente da modulação exercida por este receptor sobre a homeostase energética. / The endocannabinoid system (eCB) has been recognized as an important modulator of energy homeostasis and recent studies suggest that this system may play a possible integrator role on hydromineral homeostasis. Recent studies from our laboratory demonstrated the involvement of the type 1 cannabinoid receptor (CB1R) in the control of neurohypophyseal secretion in response to hypertonic extracellular volume expansion. Therefore, the present study aimed to clarify the involvement of the ECB system, particularly of CB1Rs, in neuronal, neuroendocrine and behavioral responses induced by 4 days of salt load (SS). Since the animals submitted to SS exhibit a well known state of hyperosmolality-induced hypophagia, we attempted to evaluate the integrated control of energy homeostasis and hydroelectrolytic balance through the introduction of a paired diet group (pair fed, PF). In order to achieve these goals, this study employed as a pharmacological tool the CB1R selective agonist, arachidonoyl-2\'-chloroethylamide (ACEA-0.1g/5L), administered intracerebroventricularly (icv). Initially, our work showed that SS increased the expression of CB1R in both supraoptic (SON) and paraventricular (PVN) nuclei of the hypothalamus, as well as in the structures of the lamina terminalis [subfornical organ (SFO), organum vasculosum of the lamina terminalis (OVLT) and median preoptic nucleus (MnPO)]. These observations were reinforced by the microscopic analysis of these brain regions by immunofluorescence, which showed increased immunostaining for CB1R in the PVN, SON and SFO in animals submitted to SS. These results also showed that most of the presynaptic CB1R-positive terminals are located predominantly in the ventral part of the SON, which is characterized by the presence of vasopressinergic neurons. The data also showed that all SS-induced responses were reversed after reintroduction of fluids (RF, water and 0,3M NaCl). On the other hand, no changes in the expression of CB1R in any of the evaluated areas were observed in the PF group. However, after RF, PF animals showed hypoosmolality and increased expression of CB1R in the LT, being the latter effect apparently mediated by increased expression of this receptor in SFO. In euhydrated animals, the central administration of ACEA produced a significant increase in food intake, being this response absent in animals submitted to SS, despite the increased expression of CB1R in the hypothalamus observed in this group. However, pretreatment with ACEA was able to potentiate SS-induced water intake, producing no significant effect on this parameter in the PF group. This study also demonstrated that SS did not alter plasma concentrations of angiotensin II (ANG II), but significantly increased plasma concentrations of corticosterone, vasopressin (AVP) and oxytocin (OT), and decreased the secretion of atrial natriuretic peptide (ANP). In animals submitted to SS, pretreatment with ACEA enhanced the secretion of corticosterone and prevented the increased secretion of AVP and OT. Moreover, no effect of ACEA was observed on the SS-induced ANG II and ANP secretion. After RF, the SS group showed normalization of hormonal plasma concentrations, and no effects of ACEA administration were verified under these experimental conditions. After RF, the PF group exhibited a decrease in OT secretion and increased plasma concentrations of ANG II, effects that were not altered by pretreatment with ACEA. Taken together, our data suggest that CB1Rs actively participate in behavioral and neuroendocrine homeostatic responses triggered by SS, and that these responses were specifically related to the control of hydromineral homeostasis and not secondary to the hyperosmolality-induced hypophagia. Therefore, we conclude that the involvement of CB1R in electrolyte homeostasis occurs in parallel and independently of the modulation exerted by this receptor on energy homeostasis.

L’insuffisance rénale chronique et la dysfonction chronique de l’allogreffe (DCA) sont associées à la fibrogenèse rénale, qui représente un enjeu majeur en santé publique et nécessite l’exploration de nouvelles cibles thérapeutiques. Dans ce contexte, nous avons étudié l’expression des gènes modulés au cours d’un modèle reconnu de fibrogenèse chez la souris (le modèle d’obstruction urétérale unilatéral, ou OUU). L'expression du gène codant pour le récepteur cannabinoïde apparait sept fois augmentée dans les reins pathologiques comparée à leurs contrôles internes. L’expression du récepteur est également significativement augmentée dans plusieurs types de néphropathies et au cours de la DCA chez l’homme. Le système cannabinoïde se compose de deux types de récepteurs, le type 1 (CB1) et le type 2 (CB2). Ceux-ci jouent des rôles opposés au cours de la fibrose hépatique, suggérant que l’inactivation de CB1 et l’activation de CB2 pourraient constituer une thérapeutique anti-fibrosante d’intérêt, indépendamment de leur implication dans le syndrome métabolique. Ainsi, nous avons montré pour la première fois que le blocage de CB1 par invalidation génétique ou par inhibition pharmacologique permet une réduction significative de la fibrose rénale induite par OUU. La potentialisation de cet effet par l’administration d’un agoniste sélectif de CB2 ne semble en revanche pas relevante, illustrant le rôle prédominant de CB1 dans ce modèle. L’étude du mécanisme réalisée in vitro sur des myofibroblastes primaires activés au TGF-β1 révèle une expression de CB1 augmentée, associée à une synthèse de collagènes significativement bloquée après un traitement par un antagoniste sélectif de CB1. Ceci suggère que l’effet anti-fibrosant dépendant de CB1 agit directement sur le myofibroblaste. Ainsi, nos travaux montrent pour la première fois l’effet anti-fibrosant de l’inactivation de CB1, avec une action directe sur la cellule effectrice de la fibrose, suggérant que CB1 représente une nouvelle cible thérapeutique et un médiateur majeur de la fibrose rénale. Son expression dans les néphropathies humaines des reins natifs présente une forte corrélation avec le taux de créatinine et pourrait constituer un nouveau biomarqueur d’atteinte rénale. / Chronic kidney disease, secondary to renal fibrogenesis, is a burden on public health. In the present study, we show that the cannabinoid 1 receptor (CB1) may be a new pathway in renal fibrogenesis, independently of its involvement in metabolic disease. We found that CB1 expression was highly expressed in kidney biopsies of patients suffering from IgA nephropathy, diabetes, and acute interstitial nephritis. We also used an experimental model of renal fibrosis, the unilateral ureteral-obstruction model, in mice. Both genetic and pharmacological invalidation of CB1 induced a profound reduction in renal fibrosis, showing its prominent role in renal fibrosis. Cannabinoid receptor 2 is also involved in renal fibrogenesis but does not potentialize the role of CB1. CB1 expression is drastically increased in myofibroblasts upon TGFß-1 stimulation. The decrease in renal fibrosis during CB1 invalidation is explained by a direct action on myofibroblasts: CB1 blockade reduced collagen expression in vitro. In addition, CB1 also modulates the macrophage infiltrate responsible for renal fibrosis in unilateral ureteral obstruction through a decrease in MCP1 synthesis, a major chemoattractant cytokine. Our study strongly suggests a major role for CB1 in the activation of myofibroblasts, which are the main effector cells in renal fibrogenesis, and suggests that CB1 may represent a major new target for treating chronic kidney disease.

Con la finalidad de explorar con profundidad las bases neurobiológicas de la adicción a cannabinoides hemos llevado a cabo diferentes estudios farmacológicos y moleculares. El sustrato neuroanatómico de la dependencia física de cannabinoides ha sido investigado en ratones que recibieron un tratamiento crónico con el agonista WIN55,212-2. En este estudio, se observó que el cerebelo y en menor grado el hipocampo y la amígdala, participan en la manifestación comportamental del síndrome de abstinencia de cannabinoides. Estas tres áreas se caracterizan por presentar una alta densidad de receptores cannabinoides CB1. Además, hemos evaluado la participación de diversos sistemas de neurotransmisión como son los sistemas opioide y purinérgico endógenos, en las respuestas comportamentales inducidas tras la administración de cannabinoides. Especialmente, nos hemos interesado por aquellas respuestas que están estrechamente relacionadas con las propiedades adictivas de dichos compuestos, como son los efectos reforzantes y aversivos y el desarrollo de dependencia física. Para ello hemos utilizado ratones modificados genéticamente. El sistema opioide endógeno ha sido relacionado con la manifestación de las propiedades adictivas de los cannabinoides. En este trabajo, mediante la utilización de ratones dobles mutantes MOR/DOR, hemos demostrado que se requiere una acción cooperativa entre ambos tipos de receptores opioides para que el síndrome de abstinencia cannabinoide se exprese enteramente. Por otro lado, los ratones con una supresión del gen que codifica para el receptor de adenosina A2A no mostraron ni preferencia de plaza ni aversión de plaza condicionadas a la administración de THC. Además, estos ratones presentaron un síndrome de abstinencia de THC de menor severidad, lo que sugiere una participación específica de los receptores A2A en efectos de los cannabinoides relacionados con sus propiedades adictivas. Finalmente, teniendo en cuenta que el sistema cannabinoide parece estar implicado en la modulación de las propiedades adictivas de otras drogas de abuso como opiáceos, etanol, cocaína y MDMA, hemos investigado la posible implicación del sistema cannabinoide en las propiedades adictivas de la nicotina. Para ello, hemos evaluado las respuestas comportamentales inducidas tras la administración aguda y crónica de nicotina en ratones deficientes del receptor cannabinoide CB1. En este sentido, nuestro principal hallazgo ha sido que las propiedades gratificantes de la nicotina no se manifiestan en los ratones mutantes sin el receptor cannabinoide CB1. Este hecho resulta de especial interés para la búsqueda de nuevas alternativas terapéuticas que faciliten el abandono del hábito tabáquico. / Cannabinoid addiction includes complex neurobiological and behavioural processes. Recently, several animal models allowing the exploration of the neurobiological basis of cannabinoid addiction have been developed. Acute cannabinoid reinforcing effects play a major role in the initiation of cannabinoid addiction, whereas the negative consequences of drug abstinence have a crucial motivational significance for relapse and maintenance of the addictive process. To further explore the neurobiological basis of cannabinoid addiction, we have conducted several pharmacological and molecular studies. The neuroanatomical substrate of cannabinoid physical dependence has been investigated in mice chronically receiving the cannabinoid agonist WIN 55,212-2. Interestingly, the cerebellum and in a lesser extent the hippocampus and the amygdala are shown to participate in the behavioural expression of cannabinoid withdrawal. All these brain areas have a high density of CB1 cannabinoid receptors. Moreover, we have evaluated the involvement of various neurotransmitter systems, such as the purinergic and opioid systems, in the behavioural responses of cannabinoids related to their addictive properties, including rewarding effects and the development of physical dependence. For this purpose, we have used genetically modified mice. Mice lacking A2A adenosine receptors reveal lower motivational responses to cannabinoids and a decreased cannabinoid withdrawal syndrome, suggesting a specific involvement of these receptors in the addictive-related properties of cannabinoids. On the other hand, the opioid system has also been implicated in the addictive properties of cannabinoids. Here, by using double mutants for mu- and delta-opioid receptors, we show that a cooperative action of both receptors is required for the entire expression of cannabinoid dependence. Finally, taking into account that the cannabinoid system has been reported to participate in the addictive properties of other drugs of abuse, such as ethanol, cocaine and MDMA, we have investigated the possible role of the cannabinoid system in the addictive properties of nicotine. We have evaluated nicotine behavioural responses in mice lacking CB1 cannabinoid receptors. In this regard, our main findings are that some acute effects and motivational responses of nicotine can be modulated by the endogenous cannabinoid system which could be of interest in order to find new therapies to facilitate tobacco smoking cessation.

Endocannabinoids are products of phospholipid-derived arachidonic acid that regulate hypothalamus-pituitary-adrenal axis activity. We hypothesize that differences in the quality and quantity of maternal dietary fat will modulate the neonatal phospholipid arachidonic acid content of the brain affecting the stress response via differences in endocannabinoid concentration of stress-activated brain areas. Dams were fed a 5% (C) or 300.10 fat diet rich in either n-6 (C, HF) or n-3 (HFF) fat during the perinatal period. PND4-5 HFF milk displays a reduced n-6/n-3 ratio compared to C and HF milk. PND10 hypothalamic and hippocampal PL AA levels are reduced in HFF pups relative to C and HF offspring; and predict endocannabinoid levels in a region-specific manner. In all pups pre-treated with an endocannabinoid receptor antagonist (AM251) or an inhibitor of the endocannabinoid degradative enzyme (URB597), basal and stress-induced ACTH secretion dose-dependently increased. Moreover, HFF pups exhibited a tendency towards reduced AM251 sensitivity under stressful conditions. These data suggest that the nature of perinatal dietary fat can differentially influence neonatal brain arachidonic acid levels and their endocannabinoid derivatives; and endocannabinoid signaling may be altered between diet groups since pups exhibit differences in sensitivity to endocannabinoid receptor blockade.

Le système opioïde contrôle la douleur et la récompense, et le récepteur opioïde mu est la cible moléculaire de l’analgésie et de la dépendance aux opiacés. Dans la première partie de la thèse, nous avons montré que ce récepteur est également nécessaire au développement de l’hyperalgie se développant lors d’une administration chronique de morphine. Dans la seconde partie de thèse, nous avons étudié l’impact des interactions entre systèmes opioïde et cannabinoïde sur les effets associés à l’administration chronique de morphine. Nous avons exploré les effets d’un prétraitement avec un agoniste sélectif du récepteur cannabinoïde CB1, l’arachidonyl-2-chloroethylamide (ACEA) sur le développement de réponses nociceptives morphiniques, le sevrage, la récompense et des comportements naturels. L’étude comportementale a été complétée par des analyses transcriptionnelles et fonctionnelles afin d’identifier les processus neuroadaptatifs mis en jeu. Nos travaux montrent que l’activation des récepteurs CB1 et Mu présentent des effets bénéfiques sur les paramètres comportementaux associés à l’addiction, suggérant un intérêt thérapeutique potentiel à associer ces composés en clinique. / The opioid system controls pain and reward, and the Mu opioid receptor plays a central role in these effects. In the first part of the thesis, we showed that Mu receptor is also involved in the development of hyperalgesia induced by chronic opiate exposure. In the second part of the thesis, we studied the impact of opioid and cannabinoid interactions on effects associated to chronic morphine administration. We explored the effects of a pretreatment with a CB1 cannabinoid receptor selective agonist, arachidonyl-2-chloroethylamide (ACEA), on morphine-associated nociceptive, withdrawal, reward and naturalistic behaviors. To complete this behavioral study, we performed transcriptional and functional analyses to identify the neuroadaptative processes involved. Our study demonstrates that dual activation of CB1 and Mu receptors has a beneficial effect on behavioral parameters related to addiction, pointing to potential usefulness of combining both medications for therapeutic interventions.